HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switchers, apply here, says HPRA

This article was originally published in OTC Bulletin

Executive Summary

Irish medicines agency, the HPRA, has said it is “open” to prescription-to-OTC switch applications, especially if they are first-in-category switches, and will offer advice to firms that apply.

You may also be interested in...



Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert

Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview. 

Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany

A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June. 

An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process

In Part 2 of this exclusive interview, Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, tells HBW Insight what the association is doing to improve the prescription-to-OTC switch process in Germany. 

Related Content

Topics

UsernamePublicRestriction

Register

RS122526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel